Among patients with tumors positive for TRK protein expression after IHC staining, the percentages confirmed as NTRK gene fusion positive after NGS were 80% (8/10) for CRC, 5% (1/21) for NSCLC, 6% (1/18) for salivary cancer, 0% (0/21) for sarcoma, and 25% (4/16) for pediatrics. This evidence concerns the gene TPM3 and colorectal carcinoma.